How VCs Are Underwriting Drug Pricing Risk in Biotech Deals

Episode notes

In this episode of The Venture Capital Podcast, Lucas and Luna explore a quiet but consequential shift in how venture capitalists evaluate biotech startups: underwriting drug pricing risk at the Series A stage. Rather than treating pricing as a commercial-stage problem, firms like Flagship Pioneering and Arch Venture Partners are now embedding pricing assumptions into term sheets using milestone-linked tranches and pricing covenants. Lucas breaks down the mechanics of 'pricing-adjusted valuations' using the example of a hypothetical oncology startup, while Luna flags the tension this creates between founders who want optionality and VCs who want downside protection. The hosts also connect the trend to recent market signals - including ARKG's 5.2% weekly decline and the broader pressure on biotech valuations in a rising-rate environment. A timely episode for anyone who thinks pricing risk only matters after FDA approval.

• Synthetic User Startups Are Venture Capital's New Frontier44 / 100
• Why VCs Are Betting on Private Space Pilots for the US Space Force76 / 100
• Why VCs Are Backing Niche AI Copilots for Every Industry72 / 100
• The Bending Spoons IPO and Why VCs Love Bootstrapped Startups60 / 100
• Why VCs Are Betting on Together AI's 800 Million Round74 / 100